Trump's Prescription Drug Price Shifts Create Uncertainty and Higher Prices for Americans

Trump's prescription drug price shifts through voluntary MFN deals and TrumpRx create uncertainty as drugmakers continue raising prices on most medications despite his promises.

Objective Facts

Since September 2025, 16 major drug companies have inked deals with the Trump administration to lower prices, but drug companies raised the prices of 872 brand-name drugs in the first two weeks of 2026. TrumpRx launched on February 5, 2026, with the administration claiming it would give Americans new options to purchase prescription drugs at lower prices. To date, the administration has reached voluntary MFN pricing agreements with 17 of the largest pharmaceutical manufacturers in the world. A Senate report by Bernie Sanders' staff found that companies with Trump deals raised the cost of hundreds of medications and launched new ones at an average price of $353,000 a year. President Trump's demand that wealthy countries in Europe spend more on drugs so the U.S. can pay less has introduced uncertainty across the continent.

Left-Leaning Perspective

House Energy and Commerce Committee Ranking Member Frank Pallone Jr. (D-NJ) characterized TrumpRx as 'all hype and no true action,' saying it 'continues the president's long history of scamming consumers'. Senate Finance Committee Ranking Member Ron Wyden reported that nearly two thirds of the drugs on TrumpRx are available for equivalent or cheaper prices elsewhere. According to a House Energy and Commerce Committee report released in February 2026, for nearly half of the 43 drugs listed on TrumpRx, there is little to no change to pre-existing discounted prices; for at least 15 drugs, a less expensive generic version is available but not disclosed on the platform; and at least seven medications already have pre-existing coupons on GoodRx at the same or nearly same price. Democrats argue that pharmaceutical companies have increased their profit margins while working with the administration, with analysis by staff for Sen. Bernie Sanders showing that combined profits of 15 companies jumped 66% over the past year to $177 billion. Democrats point to examples like Merck's Keytruda cancer drug, which rose 6% to about $210,000 a year in the U.S., far higher than prices in Japan ($37,900) and France ($88,100), and Novartis' Kesimpta multiple sclerosis drug, which increased by nearly $10,500 to $141,000 a year. Senators Dick Durbin, Elizabeth Warren, and Peter Welch raised concerns regarding questionable prescribing practices, potential conflicts of interest, and insufficient care related to the direct-to-consumer platforms to which TrumpRx directs patients. Progressive policy experts, including those cited in US News opinion by Victor Roy and Mara Heneghan, highlight that Medicare drug price negotiation, authorized under the Biden administration's Inflation Reduction Act, represents an important step already delivering results and that expanding this program should be a priority. Left-leaning coverage emphasizes that TrumpRx does not address the structural problems of pharmaceutical pricing or meaningfully help the majority of insured Americans, and downplays the administration's claims of $529 billion in savings as based on opaque deal terms.

Right-Leaning Perspective

A coalition of more than 50 conservative leaders, including Grover Norquist, president of Americans for Tax Reform; Stephen Moore, co-founder of Unleash Prosperity Now and former Trump economic adviser; Tim Chapman, president of Advancing American Freedom; and Phil Kerpen, president of American Commitment, signed a letter in February 2026 opposing codifying Trump's MFN drug pricing policy. The letter argues that an MFN pricing law would 'import socialist price controls and values into our country'. The Wall Street Journal editorial board criticized Trump over expanding drug price controls, saying 'for that trade, we could have elected Democrats'. Republicans in Congress characterize MFN pricing efforts as government overreach that would be counter to free-market ideals. Conservative leaders argue that MFN would 'reduce access to new cures and reduce U.S. global competitiveness, ceding ground to China,' and while supporters correctly identify problems with wealthy countries paying artificially lower prices, 'MFN would not solve these problems'. Washington Examiner opinion argues these proposals would 'tie U.S. drug prices to the artificially low rates set by foreign governments' and 'import the broader healthcare policies other countries manipulate to game the system, policies that ration care and disregard human life'. Conservative and market-oriented analysts have been critical of Trump's MFN policy, arguing it does little to address the root problem behind high drug costs; the Centre for Economic Policy Research argues that patent monopolies are the primary driver of exorbitant drug costs, something that neither MFN pricing nor drug price negotiation addresses. Right-leaning coverage emphasizes that Trump's approach contradicts Republican free-market principles and that the voluntary nature of the deals means their actual impact remains unverified and potentially marginal.

Deep Dive

Trump's shift toward MFN pricing represents a dramatic departure from traditional Republican free-market orthodoxy, creating an unusual coalition of unlikely critics. The core tension is between Trump's populist appeal to cost-conscious voters and conservative ideological concerns about government pricing authority. The evidence suggests three key problems with the policy's execution: First, the median list price increase for hundreds of brand-name drugs in early 2026 was 4%, identical to the prior year despite MFN deals, indicating drugmakers simply maintained price-hiking trajectories on non-negotiated drugs while making limited concessions on designated products. Second, the voluntary nature of deals means they apply only to willing participants and specific drugs, leaving pricing deals to apply to Medicaid while most Americans are on commercial health plans, and MFN pricing could have negligible impact on Medicaid patients because the program already guarantees the lowest price offered to any commercial payer. Third, the administration is working with Congress to codify voluntary agreements into law, but Republicans characterize such efforts as government overreach counter to free-market ideals, creating legislative gridlock. Each side gets something right but misses important context. Progressives correctly identify that TrumpRx offers limited scale and that most insured Americans will not benefit, but they downplay Trump's continuation of Biden's Medicare negotiation program, which is driving actual savings. Conservatives correctly note that MFN approaches may suppress innovation incentives and that voluntary deals are weaker than legislative mandates, but they misrepresent Trump's departure from free-market principles as entirely novel when similar price pressures existed under both parties. What both miss is that the core problem—U.S. patients do face significantly higher prices, with a large share of spending supporting domestic R&D, but real inefficiencies are internal, stemming from structural features of the U.S. system, most notably a highly financialized pharmaceutical sector and powerful intermediaries that capture considerable value without proportional contribution—cannot be solved by either MFN deals or traditional regulation without addressing intermediaries like pharmacy benefit managers and patent protections. Trump frequently touts his deals, claiming Americans now pay the world's lowest drug prices, but three drugs coming soon will test these claims, suggesting the real test of whether this policy shifts underlying pricing dynamics lies ahead. The administration's projections of $529 billion in savings assume manufacturers will not circumvent MFN pricing through market withdrawal or geographic segmentation, but international pharmaceutical competition and regulatory barriers make such workarounds plausible. Whether TrumpRx and MFN agreements reshape U.S. drug pricing or merely create a boutique discount option for the uninsured will become clearer as new medications enter the market and the administration attempts to codify deals into law despite congressional skepticism.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

Trump's Prescription Drug Price Shifts Create Uncertainty and Higher Prices for Americans

Trump's prescription drug price shifts through voluntary MFN deals and TrumpRx create uncertainty as drugmakers continue raising prices on most medications despite his promises.

May 28, 2026· Updated Jun 4, 2026
What's Going On

Since September 2025, 16 major drug companies have inked deals with the Trump administration to lower prices, but drug companies raised the prices of 872 brand-name drugs in the first two weeks of 2026. TrumpRx launched on February 5, 2026, with the administration claiming it would give Americans new options to purchase prescription drugs at lower prices. To date, the administration has reached voluntary MFN pricing agreements with 17 of the largest pharmaceutical manufacturers in the world. A Senate report by Bernie Sanders' staff found that companies with Trump deals raised the cost of hundreds of medications and launched new ones at an average price of $353,000 a year. President Trump's demand that wealthy countries in Europe spend more on drugs so the U.S. can pay less has introduced uncertainty across the continent.

Left says: Democrats argue TrumpRx is 'not a serious effort to lower prescription drug prices' and say Trump should instead work with them to expand Medicare drug price negotiation, make those prices more widely available to Americans with private health insurance, prevent unfair price hikes, and cap out-of-pocket costs.
Right says: The Wall Street Journal editorial board criticized Trump over expanding drug price controls, saying 'for that trade, we could have elected Democrats', reflecting conservative concerns about market interference.
✓ Common Ground
Several voices across the political spectrum acknowledge that about 60% of American adults are worried about being able to afford prescription drug costs, more than 80% consider prescription drug prices unreasonable, and most support increased regulation to lower costs, creating genuine political pressure for action on drug affordability.
Both left and right-leaning analysts note that while average brand-name list prices declined in 2026 for the first time, that shift was largely driven by Biden administration policies, including Medicare drug pricing negotiations, suggesting some acknowledgment that legislative tools have been more effective than executive deals.
Both sides point to the opacity of Trump's deals as a problem: Few details of the deals struck by the Trump administration and 17 leading pharmaceutical companies have been made public, making it hard to independently verify the projected savings, with even the White House's own rationale for secrecy creating skepticism.
Conservative critics and some Democratic moderates share concern that the agreements are opaque and unenforceable, raising questions about whether voluntary deals can achieve meaningful price reductions on their own.
Objective Deep Dive

Trump's shift toward MFN pricing represents a dramatic departure from traditional Republican free-market orthodoxy, creating an unusual coalition of unlikely critics. The core tension is between Trump's populist appeal to cost-conscious voters and conservative ideological concerns about government pricing authority. The evidence suggests three key problems with the policy's execution: First, the median list price increase for hundreds of brand-name drugs in early 2026 was 4%, identical to the prior year despite MFN deals, indicating drugmakers simply maintained price-hiking trajectories on non-negotiated drugs while making limited concessions on designated products. Second, the voluntary nature of deals means they apply only to willing participants and specific drugs, leaving pricing deals to apply to Medicaid while most Americans are on commercial health plans, and MFN pricing could have negligible impact on Medicaid patients because the program already guarantees the lowest price offered to any commercial payer. Third, the administration is working with Congress to codify voluntary agreements into law, but Republicans characterize such efforts as government overreach counter to free-market ideals, creating legislative gridlock.

Each side gets something right but misses important context. Progressives correctly identify that TrumpRx offers limited scale and that most insured Americans will not benefit, but they downplay Trump's continuation of Biden's Medicare negotiation program, which is driving actual savings. Conservatives correctly note that MFN approaches may suppress innovation incentives and that voluntary deals are weaker than legislative mandates, but they misrepresent Trump's departure from free-market principles as entirely novel when similar price pressures existed under both parties. What both miss is that the core problem—U.S. patients do face significantly higher prices, with a large share of spending supporting domestic R&D, but real inefficiencies are internal, stemming from structural features of the U.S. system, most notably a highly financialized pharmaceutical sector and powerful intermediaries that capture considerable value without proportional contribution—cannot be solved by either MFN deals or traditional regulation without addressing intermediaries like pharmacy benefit managers and patent protections.

Trump frequently touts his deals, claiming Americans now pay the world's lowest drug prices, but three drugs coming soon will test these claims, suggesting the real test of whether this policy shifts underlying pricing dynamics lies ahead. The administration's projections of $529 billion in savings assume manufacturers will not circumvent MFN pricing through market withdrawal or geographic segmentation, but international pharmaceutical competition and regulatory barriers make such workarounds plausible. Whether TrumpRx and MFN agreements reshape U.S. drug pricing or merely create a boutique discount option for the uninsured will become clearer as new medications enter the market and the administration attempts to codify deals into law despite congressional skepticism.

◈ Tone Comparison

Left-leaning coverage uses accusatory language like 'scamming consumers,' 'snake oil salesman,' and 'hype,' treating the Trump initiatives as performative deception. Right-wing critics employ ideological language like 'socialist price controls' and 'betrayal,' framing MFN as a principled problem rather than a fraud. Trump administration rhetoric emphasizes transformation and historic achievement ('biggest thing having to do with drugs in the history of the purchase of drugs'), while skeptics across ideological lines use measured criticism about opacity and limited scope.